Shares of Sientra Inc (NASDAQ:SIEN) have earned an average recommendation of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $15.00.
A number of equities analysts have commented on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $14.00 target price on shares of Sientra in a report on Sunday, October 8th. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 target price (up from $11.00) on shares of Sientra in a report on Wednesday, September 27th. BidaskClub upgraded shares of Sientra from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a report on Sunday, December 31st.
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Sientra by 11.2% during the second quarter. Vanguard Group Inc. now owns 590,311 shares of the medical instruments supplier’s stock worth $5,737,000 after acquiring an additional 59,546 shares during the last quarter. Bamco Inc. NY grew its stake in shares of Sientra by 6.4% during the third quarter. Bamco Inc. NY now owns 501,500 shares of the medical instruments supplier’s stock worth $7,723,000 after acquiring an additional 30,000 shares during the last quarter. Cloverdale Capital Management LLC grew its stake in shares of Sientra by 28.9% during the second quarter. Cloverdale Capital Management LLC now owns 492,237 shares of the medical instruments supplier’s stock worth $4,785,000 after acquiring an additional 110,495 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Sientra by 1.1% during the third quarter. Schroder Investment Management Group now owns 437,276 shares of the medical instruments supplier’s stock worth $6,730,000 after acquiring an additional 4,815 shares during the last quarter. Finally, EAM Investors LLC purchased a new stake in shares of Sientra during the third quarter worth about $3,018,000. Institutional investors and hedge funds own 76.59% of the company’s stock.
Sientra (NASDAQ:SIEN) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.06). The firm had revenue of $9.80 million during the quarter, compared to the consensus estimate of $10.54 million. Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The business’s revenue for the quarter was up 50.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. equities analysts predict that Sientra will post -3.23 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2018/01/16/sientra-inc-sien-given-average-rating-of-hold-by-brokerages.html.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.